Recent Press Releases

Biolinq Expands Series A Financing with $4.75 Million Investment

SAN DIEGO, CA – March 29, 2019 – Biolinq, a health technology company with a unique, wirelessly-enabled biosensor patch, capable of continuously monitoring multiple biomarkers, today announced it has expanded its oversubscribed Series A financing with an additional investment of $4.75 million led by the JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners. They join...


Diasome Provides Company Update

CLEVELAND, OHIO – February 14, 2019 – Diasome Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing hepatocyte directed vesicle (HDV) nanotechnology as an insulin additive to substantially improve blood glucose control for people living with diabetes, today issued a company update for the 16-month period ending December 2018. The company has completed three human clinical studies...


Pandion Therapeutics Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund

CAMBRIDGE AND BOSTON, MA – December 19, 2018 – Pandion Therapeutics, a biotechnology platform company developing therapeutics to achieve localized immunomodulation to treat autoimmune and inflammatory disease, today announced it has received an investment from the JDRF T1D Fund. This financing will enable the company to launch a type 1 diabetes (T1D)-focused program leveraging its innovative technology platform...


ImmusanT Expands Platform to Type 1 Diabetes with Investment from JDRF T1D Fund

CAMBRIDGE, Mass. – September 11, 2018 – ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, today announced that it has received an investment from the JDRF T1D Fund, a venture philanthropy fund...


Inversago Pharma receives $7 million in series A financing

MONTREAL (CANADA) – July 25, 2018 – Proceeds will support the development of novel generation cannabinoid receptor type 1 (CB1) inverse agonists for the treatment of several metabolic diseases including Prader-Willi Syndrome (PWS) and type 1 diabetes (T1D). Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue...